source
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
- FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapsesThe U.S. Food and Drug Administration sent warning letters to three manufacturers of active pharmaceutical ingredients (APIs) based in China. Two of the companies were cited for refusing to provid…raps · 4d agoRegulatoryNegative